Cure My Disease

Don't miss your cure!

 Log in / Sign up

Self-swabs could boost cervical cancer screening in kazakhstan

NCT ID NCT07111819

Prevention Sponsor: Nazarbayev University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 31, 2026 · Last updated Sep 01, 2026 · Updated 1 time

Summary

This study tests whether women in Kazakhstan will accept self-sampling kits for HPV detection, a key step in preventing cervical cancer. Researchers will distribute three different self-sampling devices to 1,000 women and survey their willingness to use them. The goal is to see if this approach can improve screening coverage, which currently reaches only about 46% of eligible women. If accepted, self-sampling could offer a more accessible alternative to clinic-based Pap tests.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Self-sampling kits for HPV detection (Evalyn Brush, Copan Self Vaginal FLOQSwabs, BGI Sentis HPV self-sampling kit)
What this could lead to
If women accept these kits, self-sampling could become a routine way to screen for cervical cancer in Kazakhstan, potentially increasing coverage and catching the disease earlier.
What could go wrong
This is a validation study, not a test of cancer outcomes. Acceptance may not translate to real-world use, and the kits may not be as accurate as clinician-collected samples.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

1,000 people

The number who actually took part.

Started

Aug 2025

Finished

Aug 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Eligible participants will be recruited from different outpatient clinics in Kazakhstan located in the different regions (western, eastern, northern, southern, and central parts) of the country, and must meet the following inclusion criteria: 1. age - women 18 years and older; 2. Intact uterine cervix (no prior total hysterectomy or trachelectomy); 3. ability to understand and answer questions/surveys in Kazakh, Russian or English. Exclusion Criteria: patients who are 1. younger than 18 years old, 2. women after total hysterectomy (or other surgery, when the uterine cervix is removed), 3. pregnant women, and 4. those who are not able to answer questions in Kazakh, Russian or English will be excluded.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cervical cancer screening are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical cancer prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cervical cancer screening

Contacts and locations

Locations

  • Outpatient units

    Astana, 010000, Kazakhstan

More trials for these conditions

Other studies related to the condition(s) this trial covers.